SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

25 Jul 2018 07:00

RNS Number : 6057V
James Halstead PLC
25 July 2018
 

25 July 2018

 

 

Pre-Close Trading Statement

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2018.

 

We are pleased to report that sales for the year were ahead of the comparative year. This represents a creditable performance in still difficult trading conditions. It is particularly pleasing to report that our UK turnover is 3% ahead of the prior year in a market that seems to be quite robust despite the well reported spending cuts and high street retailer issues.

 

In the Chairman's interim statement, announced on 29 March 2018, it was noted that adverse price pressure on raw materials was holding back the benefits of export currency gains. This continued in the second half year but was ameliorated by increased sales. The Chairman, in that statement, noted that a German competitor had entered administration and at that time we decided to undertake our largest ever re-vamp of our homogenous flooring ranges with the launch of "Palettone."

 

Palettone is a premium homogenous sheet vinyl collection, launched in May 2018. It is the largest new product development by any manufacturer in this core product area in many years. It offers a collection of 50 colours optimised for our global market and is presented in a unique, innovative sample package with full customer support from specification to installation. The feedback we have received on the collection since launch has been exceptional.

 

The costs of development trials, sampling, marketing material and related costs have been around £2 million and the product has just been launched into the global market place. The timescale that our production and marketing staff worked to was ambitious and we are delighted with the successful launch.

 

In line with best practice, we shall expense these costs rather than amortise or construct an adjustment to "underlying" earnings.

 

Consequently we are pleased to anticipate, once again, reporting record turnover and expect profits for the year to 30 June 2018 will be in line with last year.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

Telephone: 0161 767 2500

 

 

Nick Lyon - Hudson Sandler

Telephone: 020 7796 4133

 

 

Ben Thorne

Dominic Morley - Panmure Gordon

(Nominated advisor and broker)

 

Telephone: 020 7886 2500

 

Chris Hardie - Arden Partners

Telephone: 020 7614 5900

(Broker)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBZLFLVDFEBBX
Date   Source Headline
6th Dec 20198:30 amRNSAGM Statement
18th Oct 20199:51 amRNSNotice of Results
1st Oct 20197:00 amRNSPreliminary Results
18th Sep 20197:00 amRNSNotice of Preliminary Results
23rd Aug 20194:37 pmRNSPrice Monitoring Extension
30th Jul 20197:00 amRNSPre-Close Trading Statement
3rd Jul 20194:41 pmRNSNew Corporate Website
3rd Jun 201910:31 amRNSTotal Voting Rights
15th May 20198:08 amRNSDirector/PDMR Shareholding
10th May 20192:36 pmRNSDirector/PDMR Shareholding
3rd May 20192:07 pmRNSTotal Voting Rights
2nd Apr 20199:57 amRNSBlock listing Interim Review
1st Apr 20196:19 pmRNSTotal Voting Rights
29th Mar 20197:00 amRNSInterim Results
28th Mar 20191:24 pmRNSNotice of Interim Results - Update
25th Mar 20199:35 amRNSNotice of Interim Results
30th Jan 20197:00 amRNSPre Close Trading Statement
28th Jan 20191:16 pmRNSDirector/PDMR Shareholding
7th Dec 20184:13 pmRNSResult of AGM
7th Dec 20187:00 amRNSAGM Statement
19th Oct 20184:02 pmRNSAnnual Financial Report and Notice of AGM
19th Oct 20187:00 amRNSDirector/PDMR Shareholding
18th Oct 20187:00 amRNSAdditional Listing
18th Oct 20187:00 amRNSTotal Voting Rights
16th Oct 20186:13 pmRNSBlock listing Interim Review
27th Sep 20184:48 pmRNSDirector/PDMR Shareholding
26th Sep 20187:00 amRNSPreliminary Results
17th Sep 20187:00 amRNSNotice of Preliminary Results
25th Jul 20187:00 amRNSPre-Close Trading Statement
22nd May 20184:58 pmRNSRule 2.8 Announcement
22nd May 20189:39 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
21st May 20189:46 amRNSForm 8.3 - James Halstead
18th May 20182:52 pmRNSForm 8.3 - James Halstead
18th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
17th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
17th May 20187:57 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
16th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
15th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
14th May 201811:57 amRNSForm 8.5 (EPT/NON-RI)
11th May 20183:26 pmRNSDirector/PDMR Shareholding
11th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
11th May 201810:20 amRNSForm 8.3 - James Halstead
11th May 20189:07 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
10th May 20181:36 pmRNSDirector/PDMR Shareholding
10th May 201811:50 amRNSForm 8.5 (EPT/NON-RI)
10th May 20189:12 amRNSForm 8.3 - James Halstead
9th May 20183:29 pmBUSForm 8.3 - James Halstead PLC
9th May 201811:57 amRNSForm 8.5 (EPT/RI) - James Halstead PLC
9th May 201811:57 amRNSForm 8.5 (EPT/NON-RI)
8th May 20181:22 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.